L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lytix Biopharma AS
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Capital Expenditures
-kr49k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Capital Expenditures
-kr1.6m
CAGR 3-Years
67%
CAGR 5-Years
23%
CAGR 10-Years
21%
B
Bergenbio ASA
OSE:BGBIO
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Capital Expenditures
-kr15.2m
CAGR 3-Years
-16%
CAGR 5-Years
-50%
CAGR 10-Years
-36%
N
Nykode Therapeutics ASA
OSE:NYKD
Capital Expenditures
-$1.1m
CAGR 3-Years
-124%
CAGR 5-Years
-69%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Capital Expenditures?
Capital Expenditures
-49k NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Capital Expenditures amounts to -49k NOK.

What is Lytix Biopharma AS's Capital Expenditures growth rate?
Capital Expenditures CAGR 1Y
68%

Over the last year, the Capital Expenditures growth was 68%.

Back to Top